Regulatory · July 10, 2026
By Peppies · July 10, 2026 · 3 min read
The advisory committee's vote is only the first step - and the split between the FDA's own scientists and its reshaped panel is the real story.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee meets at the agency's White Oak campus to review seven peptides - BPC-157, KPV, TB-500 and MOTS-c on day one; DSIP (Emideltide), Semax and Epitalon on day two. The question in front of the panel: should any of them join the 503A Bulk Drug Substances List, the legal precondition for a licensed pharmacy to compound them under a prescription. [1]
Here's the tension worth watching. In its own briefing materials, the FDA's staff have proposed not adding the peptides, citing insufficient safety and effectiveness data. But the committee was reshaped this year and, as the Associated Press reported, now "mainly includes health professionals who prescribe, produce or promote peptides." The staff review and the panel's recommendation may not line up - and that gap is the story. [2]
Second, remember what the vote does and doesn't do. It is advisory and non-binding. Even a unanimous "yes" would not change access on its own; the FDA would still have to open formal rulemaking, a process that can take more than a year. The vote is a signal, not a switch.
Third, the public comment docket (FDA-2025-N-6895) closes July 22, the day before the meeting. Comments filed by then are provided to the committee; later ones are still considered but may not reach members before they vote. [3]
What we'll be listening for: whether the panel breaks from the staff's caution, how members handle the real gaps in human safety data, and how the panel's makeup - many members practice in this field - shapes the discussion. We'll publish a plain-English readout after the meeting.
